- Home
- FIGS vs ZYME Comparison
FIGS vs ZYME Comparison
Compare FIGS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- ZYME
- Stock Information
- Founded
- FIGS 2013
- ZYME 2003
- Country
- FIGS United States
- ZYME United States
- Employees
- FIGS N/A
- ZYME N/A
- Industry
- FIGS Apparel
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- ZYME Health Care
- Exchange
- FIGS Nasdaq
- ZYME Nasdaq
- Market Cap
- FIGS 1.1B
- ZYME 968.5M
- IPO Year
- FIGS 2021
- ZYME 2017
- Fundamental
- Price
- FIGS $6.89
- ZYME $15.05
- Analyst Decision
- FIGS Sell
- ZYME Buy
- Analyst Count
- FIGS 4
- ZYME 7
- Target Price
- FIGS $5.38
- ZYME $20.00
- AVG Volume (30 Days)
- FIGS 2.0M
- ZYME 482.0K
- Earning Date
- FIGS 11-06-2025
- ZYME 10-30-2025
- Dividend Yield
- FIGS N/A
- ZYME N/A
- EPS Growth
- FIGS N/A
- ZYME N/A
- EPS
- FIGS 0.04
- ZYME N/A
- Revenue
- FIGS $569,581,000.00
- ZYME $122,867,000.00
- Revenue This Year
- FIGS $4.63
- ZYME $107.76
- Revenue Next Year
- FIGS $3.69
- ZYME $2.35
- P/E Ratio
- FIGS $158.69
- ZYME N/A
- Revenue Growth
- FIGS 3.41
- ZYME 95.94
- 52 Week Low
- FIGS $3.57
- ZYME $9.03
- 52 Week High
- FIGS $7.31
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- FIGS 54.43
- ZYME 62.01
- Support Level
- FIGS $6.50
- ZYME $13.60
- Resistance Level
- FIGS $7.19
- ZYME $15.35
- Average True Range (ATR)
- FIGS 0.25
- ZYME 0.61
- MACD
- FIGS -0.06
- ZYME -0.01
- Stochastic Oscillator
- FIGS 48.47
- ZYME 82.63
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.